Myrbetriq(Mirabegron)
4503.T
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Astellas Pharma Inc.
$2.30B
Medicare cost, 2024
$2.30B
Medicare cost, 2024
Medicare drug plans spent $2.3 billion on Myrbetriq (mirabegron) in 2024, for 3.5 million prescriptions and refills filled by 762,665 patients. It ranks 19th among all drugs by Medicare drug plan spending. California accounts for the most spending ($207.7 million, 9% of the total). It is made by Astellas Pharma Inc. (4503.T).
Medicare cost, 2024
$2.30B
-8.5% from 2023
Prescriptions
3.5M
$665.20 per claim
Patients
763K
192,430 prescribers
Total spending, 2024
$2.30B
$3,010.74 per patient
Questions and answers
How much does Medicare spend on Myrbetriq?
Medicare prescription drug plans paid $2.30B for Myrbetriq in 2024, for 3,451,931 prescriptions and refills to 762,665 patients (down 8.5% from 2023). The average cost per claim was $665.20.
Which state spends the most on Myrbetriq?
California had the highest Medicare cost for Myrbetriq in 2024: $207.7M for 287,532 claims, followed by Texas ($194.1M).
Who prescribes Myrbetriq the most?
Emily A Levandusky, physician assistant in Cheektowaga, NY, had the highest Medicare cost for Myrbetriq in 2024: 2,740 claims costing $2.1M.
Who makes Myrbetriq?
Myrbetriq is made by Astellas Pharma Inc. (4503.T), listed in the Medicare spending data as Astellas Pharma.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Myrbetriq was $2.30B in 2024, after a high of $2.51B in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Myrbetriq, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Emily A Levandusky Cheektowaga, NY | Physician Assistant | 2,740 | 784 | $2.1M |
| Brian C Crotzer Cheektowaga, NY | Physician Assistant | 1,981 | 638 | $1.4M |
| Armen A Kassabian Burbank, CA | Urology | 1,986 | 334 | $914K |
| Qingwei R Yan Oakland, CA | Urology | 772 | 219 | $806K |
| Peter C Howard Toms River, NJ | Urology | 766 | 236 | $788K |
| Ghazaleh Rostami Nia Skokie, IL | Obstetrics & Gynecology | 830 | 283 | $771K |
| Felix CHI-Ming Yip Monterey Park, CA | Urology | 1,225 | 306 | $766K |
| Nancy L Wilcox Rochester, NY | Nurse Practitioner | 1,071 | 282 | $744K |
| Joel Lee Boston, MA | Physician Assistant | 816 | 225 | $737K |
| Richard D Cespedes Easton, MD | Urology | 1,186 | 233 | $722K |
| Carlos A Fonseca-Salgado San Juan, PR | Obstetrics & Gynecology | 808 | 279 | $697K |
| Victor Hartanto Midland Park, NJ | Urology | 812 | 212 | $695K |
| Benjamin J Haylett Williamsville, NY | Physician Assistant | 1,131 | 282 | $682K |
| Brett D Lebed Santa Maria, CA | Urology | 619 | 218 | $643K |
| Manish Gopal Somerset, NJ | Obstetrics & Gynecology | 992 | 230 | $626K |
| James E Renehan Tallahassee, FL | Urology | 748 | 201 | $602K |
| Elizabeth A Kavaler New York, NY | Urology | 881 | 246 | $573K |
| Melissa C Fischer Royal Oak, MI | Urology | 582 | 203 | $563K |
| David E Burday Tallahassee, FL | Urology | 634 | 158 | $558K |
| Benjamin C Peng New York, NY | Urology | 518 | 168 | $543K |
| Robert W Lobel Albany, NY | Obstetrics & Gynecology | 491 | 146 | $539K |
| Paul M Littman Hackettstown, NJ | Obstetrics & Gynecology | 695 | 210 | $535K |
| Michelle Buscemi Skokie, IL | Certified Nurse Midwife | 557 | 182 | $529K |
| Jessica A Witter Davenport, IA | Nurse Practitioner | 768 | 168 | $521K |
| Scott A Macdiarmid Greensboro, NC | Urology | 750 | 186 | $518K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 176,387 | 3,457,934 | 716,053 | $2.25B |
| 2023 | 189,372 | 3,650,058 | 769,612 | $2.51B |
| 2024 | 192,430 | 3,451,931 | 762,665 | $2.30B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Astellas Pharma | 3,453,189 | $2.30B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 7
- RxNorm concept IDs
- 1300791, 1300797, 1300801, 1300803, 2541233
- Application numbers
- NDA202611, NDA213801
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 39,172 side-effect reports named mirabegron, the active ingredient of Myrbetriq (reports from 2010 on). 19,045 of them (48.6%) were serious, 3,335 named a death and 8,034 named a hospital stay. The reactions named most often were drug ineffective, off label use and fatigue. 14,209 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
39,172
3,300 in 2025 (+4.8% from 2024)
Serious
48.6%
19,045 reports
Deaths named
3,335
8.5% of reports
Hospital stays
8,034
20.5% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Myrbetriq?
39,172 reports from 2010 through September 2026 named mirabegron, the active ingredient of Myrbetriq. 19,045 of them (48.6%) were serious, 3,335 named a death and 8,034 named a hospital stay.
What are the most reported side effects of Myrbetriq?
5,971 reports named drug ineffective, the reaction named most often, followed by off label use (2,852) and fatigue (2,372). In the last 5 years the reaction named most often was off label use (1,780 reports). A report can name several reactions.
How many side-effect reports named Myrbetriq in 2025?
3,300 reports were received in 2025 (+4.8% from 2024). 2026 so far: 2,119 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Myrbetriq caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Myrbetriq caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with mirabegron: Mirabegron Er
- Makers on the stock market:
4503.T·4503.T drug pipeline - Drug approvals (2 approvals on file for mirabegron) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (mirabegron) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.